Information Provided By:
Fly News Breaks for February 22, 2016
CMRX
Feb 22, 2016 | 05:54 EDT
Piper Jaffray analyst Joshua Schimmer says Chimerix over the weekend indicated that it is stopping its Phase 3 studies of brincidofovir for kidney transplant. While near-term approval of brincidofovir for allogeneic transplant is low, "there is still a good shot on goal" for approval for smallpox prevention and for treatment of active adenovirus infection, Schimmer tells investors in a research note after Chimerix announced detailed results from its Phase 3 trial of brincidofovir for the prevention of cytomegalovirus. He keeps an Overweight rating on the stock with an $18 price target.
News For CMRX From the Last 2 Days
There are no results for your query CMRX